<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HYDRALAZINE HYDROCHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(hye-dral'a-zeen)<br/><span class="topboxtradename">Alazine, </span><span class="topboxtradename">Apresoline<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">nonnitrate vasodilator</span>; <span class="classification">antihypertensive</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 25 mg, 50 mg, 100 mg tablets; 20 mg/mL vial</p>
<h1><a name="action">Actions</a></h1>
<p>Reduces BP mainly by direct effect on vascular smooth muscles of arterial-resistance vessels, resulting in vasodilation. Has
         little effect on venous-capacitance vessels. Hypotensive effect may be limited by sympathetic reflexes, which increase heart
         rate, stroke volume, and cardiac output.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Diastolic response is often greater than systolic response. Vasodilation reduces peripheral resistance and substantially improves
         cardiac output, and renal and cerebral blood flow. Postural hypotensive effect is reportedly less than that produced by ganglionic
         blocking agents.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Most commonly in stepped-care approach to treat moderate to severe hypertension. Also in early malignant hypertension and
         resistant hypertension that persists after sympathectomy.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Conjunctively with cardiac glycosides and other vasodilators in short-term treatment of acute CHF; unexplained pulmonary hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Coronary artery disease, mitral valvular rheumatic heart disease, MI, tachycardia, SLE. Safe use during pregnancy (category
         C) or lactation is established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cerebrovascular accident, advanced renal impairment, use with <small>MAO INHIBITORS</small>.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1050 mg q.i.d. <span class="rdroute">IM</span> 1050 mg q46h <span class="rdroute">IV</span> 1020 mg q46h<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 10 mg 23 times/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 37.5 mg/kg/d in 4 divided doses <span class="rdroute">IV/IM</span> 1.73.5 mg/kg/d in 4 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food; bioavailability is increased by taking it with food.</li>
<li>Discontinue gradually to avoid sudden rise in BP and acute heart failure.</li>
<li>Inform patients of the dangers of abrupt withdrawal.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give deep into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted. Use immediately after being drawn into syringe. Do not add to IV solutions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give each 10 mg or fraction thereof over 1 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Aminophylline,</b>
<b>ampicillin,</b>
<b>chlorothiazide,</b>
<b>edetate calcium disodium,</b>
<b>hydrocortisone,</b>
<b>mephentermine,</b>
<b>methohexital,</b>
<b>nitroglycerin,</b>
<b>phenobarbital,</b>
<b>verapamil.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant containers unless otherwise directed.
            Avoid freezing.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, cholangitis, hepatitis, obstructive
      jaundice). <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, tremors. <span class="typehead">CV:</span>
<span class="speceff-common">Palpitation,</span> angina, <span class="speceff-common">tachycardia,</span> flushing, paradoxical pressor response. Overdose: arrhythmia, <span class="speceff-life">shock</span>. <span class="typehead">Special Senses:</span> Lacrimation, conjunctivitis. <span class="typehead">GI:</span> Anorexia, nausea, vomiting, diarrhea, constipation, abdominal pain, paralytic ileus. <span class="typehead">Urogenital:</span> Difficulty in urination, glomerulonephritis. <span class="typehead">Hematologic:</span> Decreased hematocrit and hemoglobin, anemia, <span class="speceff-life">agranulocytosis</span> (rare). <span class="typehead">Other:</span> Nasal congestion, muscle cramps, SLE-like syndrome, fixed drug eruption, edema. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Positive <span class="alt">direct Coombs' tests</span> in patients with hydralazine-induced SLE. Hydralazine interferes with urinary <span class="alt">17-OHCS</span> determinations <span class="alt">(modified Glenn-Nelson technique).</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">beta blockers</span> and other <span class="classification">antihypertensive agents</span> compound hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 2030 min. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Duration:</span> 26 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in intestinal wall and liver. <span class="typehead">Elimination:</span> 90% rapidly excreted in urine; 10% excreted in feces. <span class="typehead">Half-Life:</span> 28 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Determine antinuclear antibody titer before initiation of therapy and periodically during prolonged therapy.</li>
<li>Make baseline and periodic determinations of BUN, creatinine clearance, uric acid, serum potassium, blood glucose, and ECG.</li>
<li>Monitor for S&amp;S of SLE, especially with prolonged therapy.</li>
<li>Monitor BP and HR closely. Check every 5 min until it is stabilized at desired level, then every 15 min thereafter throughout
            hypertensive crisis.
         </li>
<li>Monitor I&amp;O when drug is given parenterally and in those with renal dysfunction.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Monitor weight, check for edema, and report weight gain to physician.</li>
<li>
            							Note: Some patients experience headache and palpitations within 24 h after first PO dose; symptoms usually subside spontaneously.
            						
         </li>
<li>Make position changes slowly and avoid standing still, hot baths/showers, strenuous exercise, and excessive alcohol intake.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>